Pharmacielo (TSE:PCLO) has released an update.
PharmaCielo announces a landmark supply deal with Ease Labs, enabling the distribution of their pharma-grade CBD as part of São Paulo’s public health program, targeting patients with specific syndromes. The partnership signifies a major step for PharmaCielo into the Brazilian market, leveraging the growing demand for cannabinoid-based treatments. This initiative also aligns with previous legal decisions mandating government support for CBD treatments in Brazil.
For further insights into TSE:PCLO stock, check out TipRanks’ Stock Analysis page.
